Panelists:
Vivian Ott, MSc
Scientist
Inst. of Chemistry and Biotechnology
ZHAW Zurich University of Applied Sciences
Panelist
Vivian Ott, MSc
Vivian Ott is a scientist in the Center for Cell Cultivation Techniques at the ZHAW Zurich University of Applied Sciences, led by Professor Ing. Regine Eibl, PhD. Her work focuses on the development, scale-up, and process intensification of CHO cell-based fed-batch and perfusion processes for biopharmaceutical production. She has extensive experience scaling processes from the milliliter to the 200-liter scale, supporting both development and technology transfer activities.
Ott holds a Master of Science in Biotechnology from Anhalt University of Applied Sciences (Köthen, Germany) and is currently pursuing a PhD at Technische Universität Berlin, where her research centers on process intensification strategies for antibody manufacturing.
Béla Brühlmann, MSc
Field Application Scientist, Upstream
Repligen
Panelist
Béla Brühlmann, MSc
Béla Brühlmann brings over a decade of experience in biotechnology to his role as Field Application Scientist for Upstream Bioprocessing at Repligen. He supports biopharmaceutical customers across Central Europe with scientific and technical expertise, specializing in XCell® ATF and KrosFlo® TFDF technologies for process intensification. Before joining Repligen, Brühlmann held roles as Bioprocess Application Specialist at Infors HT, Project Engineer at IE Life Science Engineering, and Scientist at both the Institute of Bioprocess Technology (Zurich University of Applied Sciences, ZHAW) and the Institute of Molecular Systems Biology (ETH Zurich). He holds a BSc in Biotechnology and an MSc in Pharmaceutical Biotechnology.
- Time:
Perfusion processes have become increasingly important for manufacturing monoclonal antibodies (mAbs) because they can sustain higher cell densities, extend production runs, and boost volumetric productivity.
In this GEN webinar, Vivian Ott, a process intensification specialist, will present data demonstrating how a small-scale mAb perfusion process using the Sartorius Ambr® 250 Modular—a bioreactor not designed for perfusion—and the Repligen single-use XCell® ATF 1 Device can yield comparable outcomes to large-scale bioreactors. She will show how a continuous mAb production process, run over 23 days, achieved a volumetric productivity of 0.65 g/L/day. Attendees will also hear from Repligen’s Béla Brühlmann, who will introduce the benefits of upstream process intensification and how the XCell ATF increases productivity and reduces cost of goods from early development through commercial-scale GMP manufacturing. Key takeaways from the webinar include:
- Why small-scale perfusion models are critical for process development and seed train intensification
- How XCell® ATF technology enables increased productivity and greater efficiency
- How the linear scalability of the XCell® ATF System ensures manufacturability from process development to commercial scale
A live Q&A session will follow the presentations, offering you a chance to pose questions to our expert panelists.
Produced with support from:
The post Perfusion-Based mAb Production at 250 mL Scale Using ATF Technology appeared first on GEN – Genetic Engineering and Biotechnology News.
